Advances in Traditional Medicine

Kyung Hee Oriental Medicine Research Center (경희대학교 융합한의과학연구소)
권호 표지
DOI QR코드

DOI QR Code

Triticum aestivum (Wheatgrass) formulation: An alternate treatment for the patients with Thalassemia

  • Desai, TR (B.K. Mody Government Pharmacy College) ;
  • Solanki, JK (C.U. Shah College of Pharmacy and Research) ;
  • Buch, Pankaj (L.M. College of Pharmacy) ;
  • Goyal, RK (Department of Pediatrics, P.D.U. Medical College)
  • Published : 2008.02.29
Download PDF
⟨ Previous Next ⟩

Abstract

We have developed the tablet formulation of Triticum aestivum (wheatgrass) and investigated clinically, its effects in patients suffering from b-thalassemia (major) at K. T. Children Hospital, Civil Hospital, Rajkot. The tablets (wheatgrass powder 250 mg.) were given 3 times in a day for 9 months. Blood samples were collected at the start, after 6 months and 9 months and analyzed for various biochemical and hematological parameters. Treatment with wheatgrass formulation for 9 months produced significant decrease in hemoglobin, total RBC, eosinophil and reticulocyte counts. The mean corpuscular volume (MCV) and mean corpuscular hemoglobin concentration (MCHC) were significantly increased was significantly increased. The serum ferritin was also significantly decreased. There was no influence on serum magnesium, serum iron and Thiobarbituric acid reacting substances (TBARS). Our data indicate that treatment with wheatgrass on patients with $\beta$-thalassemia (major) may have beneficial effects in the form of a decrease in ineffective erythropoiesis, stimulation of hemoglobin synthesis in RBC, decrease in iron load and decrease in eosinophil count.

Keywords

References

  1. Adamson J, Longo D. (2001) In: Braunwald E, Fauci A, Kasper D, Hauser S, Longo D, Jameson JL (eds) Vol. 1, Anemia and polycythemia. Harrison's principles of internal medicine, pp 350
  2. Agarwal MB, Gupte SS, Viswanathan C. (1992) Long term assessment of efficacy and safety of L1, an oral iron chelator in transfusion dependent thalassaemia. Br. J. Haematol. 82, 460.466
  3. Al-Refaie FN, Sheppard LN, Nortey P, Wonke B, Hoffbrand AV.(1995) Pharmacokinetics of the oral iron chelator deferiprone (L1) in patients with iron overload. Br. J. Haematol. 89, 403.408
  4. Al-Refaie FN, Wonke B, Hoffbrand AV, Wickens DG, Nortey P, Kontoghiorghes GJ. (1992) Efficacy and possible adverse effects of the oral iron chelator 1,2- dimethyl-3-hydroxypyrid-4-one (L1) in thalassemia major. Blood 80, 593.599
  5. Ambekar SS, PhadkeMA, Mokashi GD, Bankar MP, Khedkar VA, Venkat V, Basutkar DG. (2001) Pattern of Hemoglobinopathies in Western Maharashtra. Indian Pediatr. 38, 530-534
  6. Banowetz GM, Hess JR, Carman JG. (1994) A monoclonal antibody against the plant growth regulator, abscisic acid. Hybridoma 13, 537-541
  7. Benz JE. (Jr.) (2001) In: Braunwald E, Fauci A, Kasper D, Hauser S, Longo D, Jameson JL. (eds) Vol. 1, Hemoglobinopathies. Harrison's principles of internal medicine. pp 672-674
  8. Bird A. (2001) Molecular biology. Methylation talk between histones and DNA. Science 294, 2113.2115
  9. Brittenham GM, Sheth S, Allen CJ, Farrell DE. (2001) Noninvasive methods for quantitative assessment of transfusional iron overload in sickle cell disease. Semin. Hematol. 38, 37.56
  10. Cao A, Gabutti V, Galanello R, Masera G, Modell B, Di Palma A, Piga A, Vullo C, Wonke B. (1997) Management protocol for the treatment of thalassemia patients. Thalassemia International Federation. Nicosia, Cyprus
  11. Cohen AR, Galanello R, Piga A, Dipalma A, Vullo C, Tricta F. (2000) Safety profile of the oral iron chelator deferiprone: a multicentre study. Br. J. Haematol. 108, 305.312
  12. De Franceschi L, Cappellini MD, Graziadei G, Manzato F, Olivieri O, Corrocher R, Fiorelli G, Beuzard Y, Brugnara C. (1998) The effect of dietary magnesium supplementation on the cellular abnormalities of erythrocytes in patients with ${\beta}$ thalassemia intermedia. Haematol. 83, 118-125
  13. DeSimone J, Heller P, Hall L, Zwiers D. (1982) 5- Azacytidine stimulates fetal hemoglobin synthesis in anemic baboons. Proc. Natl. Acad. Sci. USA. 79, 4428.4431
  14. Festa RS. (1985) Modern management of thlassemia. Pediatr Ann 14, 597-606
  15. Henry P, Longo D. (2001) In: Braunwald E, Fauci A, Kasper D, Hauser S, Longo D, Jameson JL. (eds) Vol.1, Enlargement of lymph nodes and spleen. Harrison's principles of internal medicine. pp 364
  16. Jandl JL. (1982) In: Autor AP. (ed) Pathology of Oxygen. pp 175-176. Academic Press, New York
  17. Jones PA, Taylor SM. (1980) Cellular differentiation, cytidine analogs, and DNA methylation. Cell 20, 85.93
  18. Lavelle D, DeSimone J, Heller P, Zwiers D, Hall L. (1986) On the mechanism of HbF elevations in the baboon by erythropoietic stress and pharmacologic manipulation. Blood 67, 1083.1089
  19. Livera MA, Tesoriere L, Pintaudi AM, Calabrese A, Maggio A, Freisleben HJ, D'Arpa D, D'Anna R, Bongiorno A.(1996) Oxidative stress and antioxidant status in ${\beta}$-thalassemia major: Iron overload and depletion of lipid-soluble antioxidants. Blood 88, 3608-3614
  20. Marwaha R, Bansal D, Kaur S, Trehan A. (2004) Wheat grass juice reduces transfusion requirement in patients with thalassemia major: A pilot study. Indian Pediatr 41, 716-720
  21. Modell B. (1994) ed: Guidelines for the control of haemoglobin disorders. World Health Organization
  22. Olivieri NF, Nathan DG, MacMillan JH. (1994) Survival in medically treated patients with homozygous beta-thalassemia. N. Engl. J. Med. 331, 574.578
  23. Schultz TF, Spiker S, Quatrano RS. (1996) Histone H1 enhances the DNA binding activity of the transcription factor EmBP-1. J. Biol. Chem. 271, 25742.25745
  24. Steinberg MH. (1988) Thalassemia: molecular pathology and management. Am. J. Med. Sci. 296, 308-321
  25. Weatherall DJ. (1997) The thalassemias. BMJ 314, 1675-1678
  26. Wigmore A. (1985) The wheatgrass Book. Avery Publishing Group. Wayne, New Jersey
  27. Zurlo MG, De Stefano P, Borgna C, Di Palma A, Piga A, Elevendi C, Di Gregorio F, Burattini MG, Terzoli S. (1989) Survival and causes of death in thalassemia major. Lancet 2, 27-30 https://doi.org/10.1016/S0140-6736(89)90264-X

Cited by

  1. A dichloromethane fraction of Triticum aestivum sprouts reduces allergic immune response through inhibiting Th2 differentiation in ovalbumin-immunized mice vol.16, pp.3, 2017, https://doi.org/10.3892/mmr.2017.7020